PVI
TERN

Pura Vida Investments’s Terns Pharmaceuticals TERN Stock Holding History

Pura Vida Investments’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-605,079
Closed -$6.16M – 165
2022
Q4 		$6.16M Sell
605,079
-123,521
-17% -$822K 0.32% 77
2022
Q3 		$4.29M Buy
+728,600
New +$2.71M 0.25% 98

Other funds holding TERN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Pura Vida Investments's TERN Position: Q1 2023 in Review

Pura Vida Investments sold out of Terns Pharmaceuticals (TERN) in Q1 2023, closing a stake of 605,079 shares — an estimated $6.16M sold.

Pura Vida Investments first reported a position in TERN in Q3 2022 and held it in 2 quarters. The position peaked at $6.16M in Q4 2022. 78 funds tracked by Wall St. Rank hold TERN as of Q1 2023.

  • Pura Vida Investments reported no remaining Terns Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Pura Vida Investments sold 605,079 Terns Pharmaceuticals shares in Q1 2023, an estimated $6.16M.
  • Pura Vida Investments first reported a position in Terns Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Pura Vida Investments's Terns Pharmaceuticals position peaked at $6.16M in Q4 2022.
  • 78 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.